2021
Treatment and prevention of viral hepatitis in pregnancy
Dionne-Odom J, Cozzi GD, Franco RA, Njei B, Tita ATN. Treatment and prevention of viral hepatitis in pregnancy. American Journal Of Obstetrics And Gynecology 2021, 226: 335-346. PMID: 34516961, PMCID: PMC8907340, DOI: 10.1016/j.ajog.2021.09.002.Peer-Reviewed Original ResearchConceptsHepatitis BViral hepatitisHepatitis AHepatitis CAntiviral therapyPregnant womenVertical transmissionImmunoglobulin GActive hepatitis BBirth dose vaccineChronic viral hepatitisHigh clinical suspicionBlood-borne transmissionElevated viral loadRisk of acquisitionVertical transmission riskMedical history reviewTenofovir disoproxil fumarateAcquisition of infectionFecal-oral transmissionRoutine prenatal screeningRoute of infectionHerpes simplex virusVaccine seriesCesarean delivery
2019
Regional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C Virus
Njei B, Esserman D, Krishnan S, Ohl M, Tate JP, Hauser RG, Taddei T, Lim J, Justice AC. Regional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C Virus. Medical Care 2019, 57: 279-285. PMID: 30807449, PMCID: PMC6436819, DOI: 10.1097/mlr.0000000000001071.Peer-Reviewed Original ResearchConceptsDirect-acting antiviral agentsHepatitis C virus infectionVeterans Affairs Healthcare SystemRural-Urban Commuting Area codesCurative HCV treatmentRural-urban designationC virus infectionElectronic health record dataHepatitis C virusPrior treatment experienceLower odds ratioHealth record dataZone improvement plan codeEligible patientsHCV treatmentAntiretroviral medicationsRural-urban residenceLiver diseaseUnadjusted analysesC virusRural-urban differencesOdds ratioMultivariable modelLower incidenceObservational study
2016
Use of transient elastography in patients with HIV–HCV coinfection: A systematic review and meta‐analysis
Njei B, McCarty TR, Luk J, Ewelukwa O, Ditah I, Lim JK. Use of transient elastography in patients with HIV–HCV coinfection: A systematic review and meta‐analysis. Journal Of Gastroenterology And Hepatology 2016, 31: 1684-1693. PMID: 26952020, PMCID: PMC5014713, DOI: 10.1111/jgh.13337.Peer-Reviewed Original ResearchConceptsHIV-HCV coinfectionTransient elastographyMeta-regression analysisDiagnostic accuracyLiver stiffnessModerate fibrosisPooled sensitivityHCV mono-infected individualsMono-infected individualsCD4 cell countCochrane Library databasesAssessment of cirrhosisSearch of PubMedNoninvasive imaging modalityNegative likelihood ratioWeb of ScienceLiver fibrosisInclusion criteriaLibrary databasesCirrhosisCell countSystematic reviewPublication biasPatientsFibrosisOptimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost‐effectiveness analysis
Njei B, McCarty TR, Fortune BE, Lim JK. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost‐effectiveness analysis. Alimentary Pharmacology & Therapeutics 2016, 44: 1090-1101. PMID: 27640785, DOI: 10.1111/apt.13798.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsBenzimidazolesCarcinoma, HepatocellularCost-Benefit AnalysisDisease ProgressionDrug Therapy, CombinationFluorenesGenotypeHepacivirusHepatitis CHumansLiver CirrhosisLiver NeoplasmsLiver TransplantationNeoplasm Recurrence, LocalQuality-Adjusted Life YearsRibavirinSofosbuvirUnited StatesConceptsHepatitis C virusLiver transplantationTime of transplantHCV recurrencePost-LTCost-effective strategyTreatment of HCVEnd-stage liver disease (MELD) scoreOptimal timingDonor LT recipientsLiver Disease scoreHCV genotype 1Hepatitis C therapyMarkov state transition modelHepatocellular carcinoma casesBase-case analysisSeparate treatment strategiesCost-effectiveness analysisAllograft failureDecompensated diseaseOngoing viraemiaPre-LTHCV treatmentLT recipientsMELD score